clinical stage life sciences venture capital investor

EnteroMedics Announces the Acquisition of the Gastric Vest System

–  At 12 Months, Gastric Vest System™ Patients Demonstrated Excess Weight Loss (EWL) of 85% and Waist Circumference Reduction of 38 Centimeters – –  Company to Host Conference Call Today at 10:00 AM Eastern Time  EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices treating obesity, metabolic diseases and other gastrointestinal disorders, announced today that itContinue Reading

EnteroMedics’ vBloc® Neurometabolic Therapy Recognized at 2017 Edison Awards

EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced it has been named a 2017 Bronze Edison Award Winner by the internationally renowned Edison Awards™ in the Health and Wellness category for its vBloc® Neurometabolic Therapy for the treatment of obesity. TheContinue Reading

Takeda Completes Enrollment of More Than 20,000 Children and Adolescents in Global Phase 3 Trial of Dengue Vaccine Candidate

– Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluates the efficacy of two doses of vaccine candidate TAK-003, administered three months apart, to protect against all four strains of dengue virus, regardless of previous dengue exposure – Study includes children and adolescents ages 4 through 16 years in eight dengue-endemic countries across Latin America andContinue Reading

Visioneering Technologies, Inc. Successfully Lists on ASX

Visioneering Technologies, Inc. (ASX:VTI) lists on the Australian Securities Exchange (ASX) VTI received strong institutional and retail investor support raising AUD$33.3 million in fully underwritten IPO VTI has developed a proprietary daily disposable contact lens called NaturalVue® (etafilcon A) Multifocal 1 Day contact lenses (NaturalVue MF) used in two major vision care applications – lossContinue Reading

Health Fidelity Launches Comprehensive Solution for Retrospective Risk Adjustment

HF360 Retrospective Risk Adjustment Provides Unprecedented Insights & Transparency into End-to-End Risk Adjustment Process Health Fidelity, a company that develops innovative technologies for the value-based care era, today launched HF360 Retrospective Risk Adjustment, a comprehensive, end-to-end solution that delivers unprecedented insights, transparency, and control over retrospective risk adjustment The HF360 Retrospective solution is a flexibleContinue Reading

US Medical Device Company Visioneering Technologies, Inc. to List On ASX – Initial Public Offer Opens

Visioneering Technologies, Inc. (VTI) has developed a proprietary daily disposable contact lens called NaturalVue™ (etafilcon A) Multifocal 1 Day Contact Lenses (NaturalVue MF) used in two major vision care applications – presbyopia (age-related loss of near-vision) and paediatric myopia (near-sightedness in children) NaturalVue MF has been cleared by the FDA and is already available inContinue Reading

EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity

vBloc® Therapy Demonstrates Significant and Sustained Weight Loss and Glycemic Control in Obese Patients with Type 2 Diabetes EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of three-year data from the Company’s VBLOC DM2 Study of vBloc® Neurometabolic TherapyContinue Reading

Commercial Patient Data Confirms Success of EnteroMedics’ vBloc® Therapy in Combination with vBloc® Achieve Program in Patients Struggling to Lose Weight

vBloc Institute Data Corroborates Pivotal Clinical Trial Results at Six and Nine Months EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced an assessment of real-world, clinical practice weight loss data in patients using the Company’s vBloc® Therapy in combination with vBloc®Continue Reading

EnteroMedics Provides Commercialization and Corporate Update

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today provided an overview of its recent commercialization and corporate achievements, and announced it will host a conference call on Wednesday, November 30, 2016 at 11:00 AM Eastern Time ahead of the Company’s anticipatedContinue Reading